Imipramine Hydrochloride Tablets USP 25mg Taj Pharma

  1. Name of the medicinal product

Imipramine Hydrochloride Tablets USP 25mg Taj Pharma

  1. Qualitative and quantitative composition

Each film coated tablet contains:
Imipramine Hydrochloride USP                       25mg
Excipients                                                        q.s.
Colour: Lake of Tartarazine

For excipients, see 6.1.

  1. Pharmaceutical form

Tablet.

  1. Clinical particulars

4.1 Therapeutic indications

1) Treatment of symptoms of depressive illness.

2) Relief of nocturnal enuresis in children.

4.2 Posology and method of administration

Posology

Adults: 1 x 25mg up to three times daily, increasing stepwise to 150-200mg. This should be reached by the end of the first week and maintained until definite improvement has occurred. The subsequent maintenance dose should be individually determined by gradually reducing the dosage, usually to about 50-100mg daily.

In patients in hospital, i.e. severe cases, the dose may be increased to 100mg three times daily until a distinct improvement is seen. Again the subsequent maintenance dose should be determined individually by reducing the dosage, usually to about 100mg daily.

Elderly: Patients over 60 years may respond to lower doses of imipramine than those recommended above. Treatment should be initiated with 10mg daily, gradually increasing to 30-50mg daily. The optimum dose should be reached after about 10 days and then continued until the end of treatment.

Children (for nocturnal enuresis only): The tablets should be administered just before bedtime.

Over 11 years (weight 35-54kg or 77-119lbs): 50-75mg daily.

8-11 years (weight 25-35kg or 55-77lbs): 25-50mg daily.

6-7 years (weight 20-25kg or 44-55lbs): 25mg daily.

Under 6 years: Not to be given to children under 6 years of age.

The dose should not exceed 75mg daily. The maximum period of treatment should not exceed three months, and withdrawal should be gradual. If relapse should occur, treatment should not be re-instituted until a full physical examination has been carried out.

Method of Administration

For oral administration.

4.3 Contraindications

  • Hypersensitivity to imipramine, any of the excipients in the tablets or cross-sensitivity to other tricyclic antidepressants of the dibenzazepine group.
  • Any degree of heart block or cardiac arrhythmias; recent myocardial infarction;
  • Severe liver disease;
  • Porphyria;
  • Narrow angle glaucoma;
  • Urine retention;
  • Mania;
  • Concomitant treatment with selective, reversible MAO-A inhibitors, e.g.moclobemide.
  • Children under six years of age.

4.4 Special warnings and precautions for use

Improvement in depression may not occur during the first two to four weeks of treatment and hence patients should be closely monitored during this period.

Hyponatraemia (usually in the elderly) has been associated with all types of antidepressants and should be considered in all patients who develop symptoms such as drowsiness, confusion or convulsions.

As tricyclic antidepressants are known to lower the convulsion threshold, imipramine should be used with extreme caution in patients with epilepsy and other predisposing factors, e.g. brain damage of varying aetiology, concomitant use of neuroleptics, withdrawal from alcohol or drugs with anticonvulsive properties (e.g. benzodiazepines). Occurrence of seizures appears to be dose-dependent.

Concomitant treatment with imipramine and electroconvulsive therapy should only be resorted to under careful supervision.

Caution is required when giving tricyclic antidepressants to patients with severe renal disease.

Caution is required when giving tricyclic antidepressants to patients with tumours of the adrenal medulla (e.g. phaeochromocytoma, neuroblastoma), as hypertensive crises may be provoked.

Many patients with panic disorders experience intensified anxiety symptoms at the start of treatment with antidepressants. This paradoxical initial increase in anxiety is most pronounced during the first few days of treatment and generally subsides within two weeks.

Caution is required in patients with hyperthyroidism or during concomitant treatment with thyroid preparations as aggravation of unwanted cardiac effects may occur.

Before starting treatment it is advisable to check the patients’ blood pressure because patients with hypotension or a labile circulation may react to the drug with a fall in blood pressure.

Although changes in the white blood cell count have been reported with imipramine only in isolated cases, periodic blood cell counts and monitoring for symptoms such as fever and sore throat are called for, particularly during the first few months of therapy. (See section 4.8).

Periodic monitoring of hepatic enzyme levels is recommended in patients with liver disease.

Monitoring of cardiac function is indicated in elderly patients.

Because of its anticholinergic properties, imipramine should be used with caution in patients with a history of increased intra-ocular pressure, narrow angle glaucoma, or urinary retention (e.g. diseases of the prostate).

Caution is required in patients with chronic constipation. Tricyclic antidepressants may cause paralytic ileus, particularly in elderly and bedridden patients.

Before general or local anaesthesia, the anaesthetist should be aware that the patient has been receiving imipramine. Anaesthetics given during tri/tetracyclic antidepressant therapy may increase the risk of arrhythmias and hypotension (see section 4.5).

An increase in dental caries has been reported during long-term treatment with tricyclic antidepressants. Regular dental check-ups are therefore advisable during long-term treatment.

Decreased lacrimation and accumulation of mucoid secretions due to the anticholinergic properties of tricyclic antidepressants may cause damage to the corneal epithelium in patients with contact lenses.

Imipramine may cause anxiety, feelings of unrest and hyperexcitation in agitated patients and patients with accompanying schizophrenic symptoms.

Activation of psychosis has been observed occasionally in schizophrenic patients receiving tricyclic antidepressants. Hypomanic or manic episodes have also been reported during a depressive phase in patients with cyclic affective disorders receiving treatment with a tricyclic antidepressant. In such cases it may be necessary to reduce the dosage of imipramine or to withdraw it and administer an antipsychotic agent. After such episodes have subsided, low dose therapy with imipramine may be resumed if required.

In predisposed and elderly patients, imipramine may, particularly at night, provoke pharmacogenic (delirious) psychoses, which disappear without treatment within a few days of withdrawing the drug. Agitation, confusion and postural hypotension may occur.

Abrupt withdrawal should be avoided because of possible adverse reactions. (See section 4.8).

Behavioural disturbances may occur in children receiving treatment with imipramine for the treatment of nocturnal enuresis.

Suicide/suicidal thoughts or clinical worsening

Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.

Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.

Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.

4.5 Interaction with other medicinal products and other forms of interaction

  • MAO inhibitors (MAOIs): Imipramine should not be administered for at least three weeks after discontinuation of treatment with MAO inhibitors (there is a risk of severe symptoms such as hypertensive crisis, hyperpyrexia, myoclonus, agitation, seizures, delirium and coma). This also applies when giving a MAO inhibitor after previous treatment with imipramine. In both instances imipramine or the MAO inhibitor should initially be given in small, gradually increasing doses and its effects monitored. There is evidence to suggest that tricyclic antidepressants may be given as little as 24 hours after a reversible MAO inhibitor such as moclobemide, but the three week wash-out period must be observed if the MAO inhibitor is given after a tricyclic antidepressant has been used.
  • Selective serotonin reuptake inhibitors (SSRIs): Co-medication may lead to additive effects on the serotonergic system. Fluoxetine and fluvoxamine may also increase the plasma concentrations of imipramine, with corresponding adverse effects, resulting in increased plasma levels of tricyclic antidepressants, a lowered convulsion threshold and seizures.
  • CNS depressants: Tricyclic antidepressants may also potentiate the CNS depressant effects of alcohol and central depressant drugs (e.g.barbiturates, benzodiazepines or general anaesthetics). (See section 4.4).
  • Alprazolam and disulfiram: It may be necessary to reduce the dosage of imipramine if it is administered concomitantly with alprazolam or disulfiram.
  • Neuroleptics: Concomitant use may result in increased plasma levels of tricyclic antidepressants, a lowered convulsion threshold and seizures. Combination with thioridazine may produce severe cardiac arrhythmias.
  • Adrenergic neurone blockers: Imipramine may diminish or abolish the antihypertensive effects of guanethidine, debrisoquine, bethanidine, reserpine, α-methyldopa and clonidine. Patients requiring co-medication for hypertension should therefore be given antihypertensives of a different type (e.g.vasodilators).
  • Beta-blockers: Blood concentrations of imipramine may be increased by drugs such as labetalol and propranolol. The clinical importance of these interactions is uncertain.
  • Diuretics: Concurrent use of a tricyclic antidepressant and a diuretic may increase the risk of postural hypotension.
  • Alpha2-adrenoceptor stimulants: concomitant use of apraclonidine or brimonidine should be avoided.
  • Anticoagulants: Tricyclic antidepressants may potentiate the anti-coagulant effect of coumarin drugs by inhibiting hepatic metabolism of anticoagulants. Careful monitoring of plasma prothrombin is therefore advised.
  • Anticholinergic agents: Tricyclic antidepressants may potentiate the effects of these drugs (e.g.phenothiazine, antiparkinsonian agents, antihistamines, atropine, biperiden) on the eye, central nervous system, bowel and bladder.
  • Sympathomimetic drugs: Imipramine may potentiate the cardiovascular effects of adrenaline (epinephrine), ephedrine, isoprenaline, noradrenaline (norepinephrine), phenylephrine and phenylpropanolamine (e.g.as contained in local anaesthetic preparations and nasal decongestants).
  • Quinidine: Tricyclic antidepressants should not be employed in combination with anti-arrhythmic agents of the quinidine type.
  • Liver enzyme inducers: Drugs which activate the hepatic mono-oxygenase enzyme system (e.g.barbiturates, carbamazepine, phenytoin, nicotine and oral contraceptives) may accelerate the metabolism and lower plasma concentrations of imipramine, resulting in decreased efficacy. Plasma levels of phenytoin and carbamazepine may increase, with corresponding adverse effects. It may be necessary to adjust the dosage of these drugs.
  • Cimetidine, methylphenidate: These drugs may increase the plasma levels of imipramine whose dosage should therefore be reduced.
  • Oestrogens: There is evidence that oestrogens can sometimes paradoxically reduce the effects of imipramine yet at the same time cause imipramine toxicity.
  • Antiviral agents: Drugs such as ritonavir have been reported to increase plasma concentrations of antidepressant drugs.
  • Calcium channel blockers: Blood levels of imipramine may be increased by calcium channel blockers such as diltiazem and verapamil.
  • Nitrates: Reduced salivary secretion may lessen the effectiveness of sub-lingual nitrate preparations.
  • Dopaminergic agents: CNS toxicity may be enhanced when tricyclic antidepressants are used in conjunction with dopaminergic drugs such as selegiline and entacapone.
  • Centrally acting appetite suppressants: Concomitant use is not recommended due to the increased risk of CNS toxicity.
  • Antineoplastic drugs: concomitant use of altretamine should be avoided due to the risk of severe postural hypotension.

Tricyclic antidepressants may also interact with the following drug classes:

  • Analgesics: Possible increase in risk of side effects (nefopam), convulsions (tramadol), sedation (opioid analgesics) or ventricular arrhythmias.
  • Anti-arrhythmics: Increased risk of ventricular arrhythmias with drugs, which prolong the QT interval.
  • Muscle relaxants: Enhanced muscle relaxant effect of baclofen.

4.6 Pregnancy and lactation

There is no evidence of the safety of the drug in human pregnancy. There have been isolated reports of a possible connection between the use of tricyclic antidepressants and adverse effects (developmental disorders) on the foetus. Treatment with imipramine should be avoided during pregnancy, unless the anticipated benefits justify the potential risk to the foetus.

Neonates whose mothers had taken imipramine up until delivery have developed dyspnoea, lethargy, colic, irritability, hypotension or hypertension, tremor or spasms, during the first few hours or days. If possible, imipramine should be gradually withdrawn at least 7 weeks before the calculated date of confinement.

As imipramine is excreted in breast milk, it should not be administered to nursing mothers unless considered essential when the mother should be advised to cease breast feeding.

4.7 Effects on ability to drive and use machines

Patients should be warned

  • That blurred vision, drowsiness and other CNS symptoms (see section 4.8) may occur.
  • Against possible hazards such as driving a car, operating machinery or doing anything which may require alertness or quick actions.
  • That alcohol or other drugs may potentiate these effects (see section 4.5).

4.8 Undesirable effects

The following frequency estimates are used: frequent >10%, occasional >1-10%, rare >0.001-1%, isolated cases <0.001%

If severe neurological or psychiatric reactions occur, imipramine should be withdrawn.

Elderly patients are particularly sensitive to anticholinergic, neurological, psychiatric, or cardiovascular effects. Their ability to metabolise and eliminate drugs may be reduced, leading to a risk of elevated plasma concentrations at therapeutic doses.

Effects on the central nervous system: fatigue, drowsiness, restlessness, delirium, confusion, disorientation, hallucinations (particularly in geriatric patients and those suffering from Parkinson’s disease), increased anxiety, agitation, sleep disturbances, swings from depression to hypomania or mania have been reported occasionally.

Activation of psychotic symptoms has been reported rarely.

In isolated cases aggressiveness has been reported.

Paranoid delusion may be exacerbated during treatment with tricyclic antidepressants. These are more frequently seen in elderly patients or those on high doses.

Cases of suicidal ideation and suicidal behaviours have been reported during Imipramine therapy or early after treatment discontinuation (see section 4.4).

Neurological effects: tremor has been reported frequently.

Paraesthesia, headache and dizziness have been reported occasionally.

Epileptic seizures have been reported rarely.

In isolated cases EEG changes, myoclonus, weakness, extrapyramidal symptoms, ataxia, speech disorders, drug fever has been reported.

Effects on the cardiovascular system: Sinus tachycardia and clinically irrelevant ECG changes (T and ST changes) in patients of normal cardiac status, and postural hypotension have been reported frequently. Cardiac arrhythmias and severe hypotension are likely to occur with high dosage or in deliberate overdosage. They may also occur in patients with pre-existing heart disease taking normal dosage.

Arrhythmias, conduction disorders (widening of QRS complex and PR interval, bundle-branch block), palpitations have been reported occasionally.

Isolated cases of increased blood pressure, cardiac decompensation, peripheral vasospastic reactions have been reported.

Anticholinergic effects: dry mouth, constipation, sweating, disturbances of visual accommodation, blurred vision, hot flushes have been frequently reported.

Disturbances of micturition have been occasionally reported.

Isolated cases of mydriasis, glaucoma and paralytic ileus have been reported.

Effects on the gastro-intestinal tract:

Nausea, vomiting, anorexia has been reported occasionally.

Isolated cases of stomatitis, tongue lesions, abdominal disorders have been reported.

Hepatic effects: Elevated transaminases have been reported occasionally.

Impaired liver function has been reported rarely.

Isolated cases of hepatitis with or without jaundice have been reported.

Effects on the skin: Allergic reactions (such as urticaria, skin rash) have been reported occasionally.

Isolated cases of oedema (local or generalised), photosensitivity, pruritus, petechiae, hair loss have been reported.

Effects on the endocrine system and metabolism: weight gain has been reported frequently.

Disturbances in libido and potency have been reported occasionally.

Isolated cases of enlarged mammary glands, galactorrhoea, SIADH (syndrome of inappropriate antidiuretic hormone secretion), increase or decrease in blood sugar, weight loss have been reported.

Hyponatraemia, usually in the elderly, has been associated with all types of antidepressants (see section 4.4).

Hypersensitivity: Isolated cases of allergic alveolitis (pneumonitis) with or without eosinophilia, systemic anaphylactic/anaphylactoid reactions including hypotension have been reported.

Effects on the blood: isolated cases of agranulocytosis, bone marrow depression including leucopenia, eosinophilia and thrombocytopenia have been reported. It is advisable to perform blood counts during treatment with tritetracyclic antidepressants, especially if the patient develops fever, sore throat or other signs of infection. (See section 4.4)

Effects on the sense organs: tinnitus has been reported.

Miscellaneous effects: although not indicative of addiction, withdrawal symptoms may occur on abrupt cessation of therapy and include nausea, vomiting, abdominal pain, diarrhoea, headache, insomnia, nervousness, anxiety, irritability and excessive perspiration (see section 4.4).

Respiratory depression, agitation and withdrawal symptoms have been reported in neonates whose mothers received imipramine during the last trimester of pregnancy.

Class effects

Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to this risk is unknown.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

4.9 Overdose

The signs and symptoms of overdose with imipramine are similar to those reported with other tricyclic antidepressants. Cardiac abnormalities and neurological disturbances are the main complications. In children accidental ingestion of any amount should be regarded as serious and potentially fatal.

Signs and symptoms: Symptoms generally appear within 4 hours of ingestion and reach a maximum severity after 24 hours. Owing to delayed absorption (increased anticholinergic effect due to overdose), long half-life and enterohepatic recycling of the drug, the patient may be at risk for up to 4-6 days. Major symptoms of overdosage include:

  • Effects on the central nervous system: drowsiness, stupor, coma, ataxia, restlessness, agitation, enhanced reflexes, muscular rigidity, athetoid and choreiform movements, convulsions.
  • Effects on the cardiovascular system include: hypotension, tachycardia, arrhythmia, conduction disorders, heart failure and, in very rare cases, cardiac arrest.
  • In addition, respiratory depression, cyanosis, shock, vomiting, fever, hydriasis, sweating and oliguria or anuria may occur.

Treatment: There is no specific antidote to imipramine. Treatment is essentially symptomatic and supportive. Gastric lavage and forced emesis should be employed immediately if the patient is fully conscious to reduce absorption of the drug. If the patient has impaired consciousness, the airway should be secured with a cuffed endotracheal tube before beginning lavage, and vomiting should not be induced. These measures are recommended for up to 12 hours or even longer after the overdose, since the anticholinergic effect of the drug may delay gastric emptying. Administration of activated charcoal may help reduce drug absorption.

Patients presenting with major symptoms of overdosage, particularly children, should be nursed in an intensive care unit for at least 72 hours where full support of vital functions is possible.

Treatment of symptoms is based on modern methods of intensive care with continuous monitoring of cardiac function, blood gases and electrolytes, and if necessary emergency measures such as: anticonvulsive therapy, artificial respiration, insertion of a temporary cardiac pacemaker, plasma expander, dopamine or dobutamine administered by intravenous drip, resuscitation.

Any serious overdosage requires continuous cardiac monitoring for at least 48 hours and dysrhythmias must be treated on an individual basis. Respiratory insufficiency may necessitate intubation and ventilation, and convulsions may be controlled with intravenous diazepam.

Physostigmine should not be used following an overdosage of imipramine as it has been reported that physostigmine may cause severe bradycardia, asystole and seizures. Haemodialysis or peritoneal dialysis is ineffective because of the low plasma concentrations of imipramine.

  1. Pharmacological properties

5.1 Pharmacodynamic properties

Pharmacotherapeutic group

Tricyclic antidepressant. Noradrenaline (NA) and serotonin (5HT) re-uptake inhibitor.

Mechanism of action

Imipramine is a tricyclic antidepressant and has several pharmacological actions including alpha-adrenolytic, antihistamine, anticholinergic and 5HT-receptor blocking properties. However, the main therapeutic activity is believed to be inhibition of the neuronal re-uptake of noradrenaline and 5HT. Imipramine is a so-called “mixed” re-uptake blocker, i.e. it inhibits the reuptake of NA and 5HT to about the same extent.

5.2 Pharmacokinetic properties

Absorption: Imipramine is absorbed quickly and completely following oral administration. The intake of food has no effect on its absorption and bioavailability. During its first passage through the liver, orally administered imipramine becomes partly converted to desmethylimipramine, a metabolite that also exhibits antidepressant activity.

During oral administration of 50mg 3 times daily for 10 days, the mean steady-state plasma concentrations of imipramine and desmethylimipramine were 33-85ng/ml and 43-109ng/ml respectively. Owing to lower clearance in the plasma, resulting in increased systemic availability, elderly patients require lower doses of imipramine than patients in intermediate age groups. Renal impairment is not expected to have any influence on the kinetics of unchanged imipramine and its desmethyl metabolite since both are excreted only in small amounts by the kidneys.

Distribution: About 86% of imipramine binds to plasma proteins. Concentrations of imipramine in the cerebrospinal fluid and the plasma are highly correlated. The mean distribution volume is about 21L/kg.

Imipramine and its metabolite desmethylimipramine both pass into breast milk in concentrations similar to those found in the plasma.

Biotransformation: Imipramine is extensively metabolised in the liver. It is cleared mainly by demethylation and to a lesser extent by hydroxylation. Both metabolic pathways are under genetic control.

Elimination: Imipramine is eliminated from the blood with a mean half-life of about 19 hours. About 80% is excreted in the urine and about 20% in the faeces, mainly in the form of inactive metabolites. Urinary excretion of unchanged imipramine and of the active metabolite desmethylimipramine is about 5% and 6% respectively. Only small quantities of these are excreted in the faeces.

Characteristics in patients: Owing to reduced metabolic clearance, plasma concentrations of imipramine are higher in elderly patients than in younger patients.

In children, the mean clearance and elimination of half-life does not differ significantly from adult controls but the between-patient variability is high.

In patients with severe renal impairment, no change occurs in renal excretion of imipramine and its biologically active unconjugated metabolites. However, steady-state plasma concentrations of the conjugated metabolites, which are considered to be biologically inactive are elevated. The clinical significance of this finding is not known.

5.3 Preclinical safety data

Imipramine has no mutagenic or carcinogenic potential. Studies in four species (mouse, rat, rabbit and monkey) led to the conclusion that orally administered imipramine has no teratogenic potential. Experiments with high doses of parenterally administered imipramine resulted mainly in severe maternal and embryotoxic effects, they were thus inconclusive with regard to teratogenic effects.

  1. Pharmaceutical particulars

6.1 List of excipients

Carnauba wax, Colloidal silica Gelatin, Lactose, Magnesium stearate, Maize starch, Polyvidone, Stearic acid, Sodium hydroxide.

6.2 Incompatibilities

None known.

6.3 Shelf life

3 years

6.4 Special precautions for storage

Store below 25°C in a dry place.

6.5 Special precautions for disposal and other handling

Not applicable.

7. Manufactured By:
Taj Pharmaceuticals Ltd. (Mumbai, India)
Unit No. 214, Old Bake House,
Maharashtra Chambers of commerce Lane,Fort,
Mumbai-400001 at: Ahmedabad- Gujarat, INDIA.

 

Imipramine Tablets USP 25 mg Taj Pharma

Patient information leaflets:

Read all of this leaflet carefully before you start taking this medicine.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctoror pharmacist.
  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their

symptoms are the same as yours.

What is in this leaflet

  1. What Imipramine tablets are and what they are used for
  2. Before you take
  3. How to take
  4. Possible side effects
  5. How to store
  6. Further information

 

  1. What Imipramine tablets are and what they are used for

Imipramine belongs to a group of medicines called tricyclic antidepressant drugs. These medicines alter the levels of chemicals in the brain to relieve the symptoms of depression. Imipramine is used:

  • to treat the symptoms of depression.
  • for the relief of bed-wetting at night by children.
  1. Before you take

Do not take Imipramine tablets and tell your doctor if you or your child (if they are the patient):

  • are allergic (hypersensitive) to imipramine, other tricyclic antidepressants or any of the other ingredients (see section 6). The 10mg tablets contain sunset yellow (E110) and aramanth (E123) and the 25mg tablets contain propylhydroxybenzoate (E216) and methylhydroxybenzoate (E218) which may cause allergic reactions which could be delayed
  • have heart disease such as irregular heart beats, heart block or have recently had a heart attack
  • suffer from periods of increased and exaggerated behaviour (mania)
  • have severe liver disease
  • suffer with porphyria (a genetic disorder of the red blood cells haemoglobin causing skin blisters, abdominal pain and brain/nervous system disorders)
  • are not able to pass water
  • have increased pressure in the eye (glaucoma)
  • are taking monoamine oxidase inhibitors (MAOI) or you have taken MAOIs within the previous 14 days for depression
  • if the child is under 6 years old.

Thoughts of suicide and worsening of your depression or anxiety disorder

If you are depressed and/or have anxiety disorders you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.

You may be more likely to think like this:

  • If you have previously had thoughts about killing or harming yourself.
  • If you are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviour in young adults (less than 25 years old) with psychiatric conditions who were treated with an antidepressant.

If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away.

You may find it helpful to tell a relative or close friend that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour.

Check with your doctor or pharmacist before taking

Imipramine tablets if you or your child (if they are the patient):

  • have any psychiatric disorder (eg schizophrenia or manic depression)
  • are withdrawing from alcohol or medicines used to treat fits
  • have ever had glaucoma or an enlarged prostate gland
  • have an overactive thyroid gland and are taking medicines to treat a thyroid disorder
  • have a history of epilepsy or brain damage
  • have low blood pressure or poor circulation
  • have severe kidney disease
  • have a tumour of the adrenal gland (eg phaeochromocytoma or neuroblastoma)
  • suffer from panic attacks
  • suffer from long term constipation
  • wear contact lenses
  • are being given electroconvulsive therapy (ECT)
  • are due to have any surgery, including dental, that involves an anaesthetic.

Taking other medicines

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. Especially:

  • medicines to treat epilepsy such as barbiturates, phenytoin, carbamazepine, phenobarbital
  • medicines called “benzodiazepines” such as diazepam, nitrazepam, oxazepam, alprazolam
  • medicines to treat depression, such as selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, fluvoxamine
  • disulfiram to treat alcohol addiction
  • nicotine replacement therapy
  • methylphenidate (used to treat attention deficit/hyperactivity disorder (ADHD))
  • medicines to stop your blood clotting (eg warfarin)
  • antihistamines (medicines to treat allergies)
  • altretamine (to treat some types of cancer)
  • apraclonidine and brimonidine (to treat glaucoma)
  • baclofen (a muscle relaxant)
  • painkillers such as nefopam, tramadol, codeine, dihydrocodeine
  • medicines to treat some heart conditions such as diltiazem, verapamil, labetalol, propranolol, quinidine
  • medicines to treat angina that you spray or dissolve under your tongue (eg glyceryl trinitrate “GTN”, isosorbide dinitrate)
  • any medicines to treat high blood pressure such as guanethidine, debrisoquine, bethanidine methyldopa, reserpine, clonidine or diuretics (“water” tablets)
  • medicines to treat some mental illnesses such as thioridazine, chlorpromazine
  • entacapone or selegiline (to treat Parkinson’s disease)
  • oral contraceptives (“the pill”) or hormone replacement therapy (HRT)
  • appetite suppressants
  • sympathomimetic medicines such as adrenaline (epinephrine), ephedrine, isoprenaline, noradrenaline (norepinephrine), phenylephrine and phenylpropanolamine (these may be present in many cough and cold remedies or local anaesthetics)
  • ritonavir (to treat HIV).

Pregnancy and breast-feeding

Imipramine tablets should not be taken during pregnancy or if breast-feeding. If Imipramine tablets are taken in the last 3 months the baby may be born with breathing difficulties, lethargy, colic, irritability, changes in blood pressure, tremors, spasm. Imipramine tablets should be withdrawn at least 7 weeks before the expected delivery date.

Driving and using machines

Imipramine may impair your alertness or cause drowsiness or blurred vision, alcohol can make these symptoms worse. Make sure you are not affected before you drive or operate machinery.

Blood tests

Whilst taking Imipramine tablets your doctor will regularly monitor your blood cell levels or liver function.

Dental check ups

As Imipramine tablets can cause problems with your teeth, it is advisable to have regular dental checks ups.

Sugar intolerance

If you have been told you have an intolerance to some sugars, contact your doctor before taking this medicine, as it contains types of sugars called lactose or sucrose.

  1. How to take

Always take Imipramine tablets exactly as your doctor has told you. If you are not sure, check with your doctor or pharmacist.

Swallow the tablets with a glass of water.

You are advised not to drink alcohol with this medicine.

Doses

Depression:

Adults – 25mg three times a day increasing to 150mg-200mg a day in divided doses. In severe cases (treated in hospital) the dose may be increased up

to a maximum of 100mg three times a day. The usual maintenance dose is between 50mg and 100mg a day in divided doses.

Elderly (over 60 years) – Initially 10mg a day increasing to 30-50mg a day.

Nightly bedwetting:

Children only, to be taken at bedtime (for no longer than 3 months and up to a maximum of 75mg a day):

Over 11 years (35-54kg) – 50-75mg a day.

8-11 years (25-35kg) – 25-50mg a day.

6-7 years (20-25kg) – 25mg a day.

Under 6 years – not recommended.

If you take more than you should

If you or the patient (or someone else) swallow a lot of tablets at the same time, or you think a child may have swallowed any, contact your nearest hospital casualty department or tell your doctor immediately. Symptoms of an overdose include fast or irregular heart beat, low blood pressure, drowsiness, fits, coma, agitation, muscle rigidity, being sick or fever.

If you forget to take the tablets

Do not take a double dose to make up for a forgotten dose. If you forget to take a dose, take another as soon as you remember and then your next dose at the usual time.

If you stop taking the tablets

Talk to your doctor before you stop taking the tablets and follow their advice as you may experience withdrawal symptoms (see section 4).

  1. Possible side effects

Like all medicines, Imipramine tablets can cause side effects, although not everybody gets them.

Stop taking the tablets and contact a doctor at once if you have the following allergic reaction, pneumonitis (fever, chills, cough, difficulty breathing, unusual weight loss, feeling sick), a skin rash, which may be itchy, sensitivity to the sun or sun lamps, puffy, swollen face or tongue, which may be severe causing shortness of breath, shock and collapse.

Tell your doctor if you notice any of the following side effects or notice any other effects not listed:

Blood: reduction in some blood cells (you may experience a sore throat, mouth ulcers and recurring infections, bleeding or bruising easily) Endocrine system and metabolism: disturbances in sexual function or sex drive, breast swelling in men and women, production or over-production of breast milk, changes in blood sugar levels, weight gain or loss, SIADH (syndrome of inappropriate antidiuretic hormone secretion)

Brain and central nervous system: disorientation, dizziness, tiredness or sleepiness, weakness, headache, difficulty concentrating, confusion, agitation, mood swings, aggressiveness, difficulty sleeping, delusions, seeing things that are not there, anxiety, restlessness, pins and needles, tremor, muscle spasm or lack of muscle control, speech problems, fits. Anticholinergic effects (dry mouth, constipation, blurred or double vision, sweating, hot flushes, difficulty passing water (urine), dilation of the pupil of the eye, glaucoma and blockage of the small intestine)

Heart: feeling faint when getting up (postural hypotension), high or severely low blood pressure, fast/racing heart, palpitations, irregular heart-beats, changes in ECG readings

Stomach and intestines: feeling or being sick, loss of appetite, inflammation of the mucus membranes in the mouth, tongue lesions.

Liver: impaired liver function, hepatitis, including changes in liver function (as seen in blood tests), jaundice (yellowing of the skin and/or whites of the eyes) Other: hair loss, ringing in the ears, small purple red spots. An increase risk of bone fractures has been observed in patients taking this type of medicine.

Withdrawal symptoms: feeling or being sick, stomach pain, diarrhoea, difficulty sleeping, nervousness, anxiety, headache, irritability Children: changes in behaviour.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

  1. How to store

Keep out of the sight and reach of children.

Store below 25°C in a dry place.

Do not use Imipramine tablets after the expiry date stated on the label/carton/bottle. The expiry date refers to the last day of that month.

Return any unused medicines to your pharmacist for safe disposal.

  1. Further information

The active substance is imipramine hydrochloride. Each tablet contains either 25mg of the active ingredient.

The other ingredients are carnauba wax, colloidal silica, gelatin, lactose, magnesium stearate, maize starch, polyvidone, stearic acid, sodium hydroxide.

What Imipramine tablets look like and contents of the pack

Imipramine tablets are circular coated tablets.

Pack sizes are 10 tablets

7. Manufactured By:
Taj Pharmaceuticals Ltd. (Mumbai, India)
Unit No. 214, Old Bake House,
Maharashtra Chambers of commerce Lane,Fort,
Mumbai-400001 at: Ahmedabad- Gujarat, INDIA.

Related Products

Taj Generics (Taj Pharma) provides a wide range of products to the Indian market, including an extensive range of generics and specialty products; Our products cover a vast array of therapeutic categories, and we offer an extensive range of dosage forms and delivery systems including oral solids, controlled-release, steriles, injectables, topicals, liquids, transdermals, semi-solids and high-potency products. Our Generics portfolio offers over 1500 products in the major therapeutic areas of gastro-intestinal, cardiovascular, pain management, oncology, anti-infectives, paediatrics and dermatology.